201 related articles for article (PubMed ID: 16026004)
1. Regional intestinal absorption and biliary excretion of fluvastatin in the rat: possible involvement of mrp2.
Lindahl A; Sjöberg A; Bredberg U; Toreson H; Ungell AL; Lennernäs H
Mol Pharm; 2004; 1(5):347-56. PubMed ID: 16026004
[TBL] [Abstract][Full Text] [Related]
2. Concentration- and region-dependent intestinal permeability of fluvastatin in the rat.
Lindahl A; Sandström R; Ungell AL; Lennernäs H
J Pharm Pharmacol; 1998 Jul; 50(7):737-44. PubMed ID: 9720622
[TBL] [Abstract][Full Text] [Related]
3. Disposition of fluvastatin, an inhibitor of HMG-COA reductase, in mouse, rat, dog, and monkey.
Tse FL; Smith HT; Ballard FH; Nicoletti J
Biopharm Drug Dispos; 1990; 11(6):519-31. PubMed ID: 2207302
[TBL] [Abstract][Full Text] [Related]
4. Multiple efflux pumps are involved in the transepithelial transport of colchicine: combined effect of p-glycoprotein and multidrug resistance-associated protein 2 leads to decreased intestinal absorption throughout the entire small intestine.
Dahan A; Sabit H; Amidon GL
Drug Metab Dispos; 2009 Oct; 37(10):2028-36. PubMed ID: 19589874
[TBL] [Abstract][Full Text] [Related]
5. Surface activity and concentration dependent intestinal permeability in the rat.
Lindahl A; Persson B; Ungell AL; Lennernäs H
Pharm Res; 1999 Jan; 16(1):97-102. PubMed ID: 9950286
[TBL] [Abstract][Full Text] [Related]
6. Disposition of [3H]fluvastatin following single oral doses in beagle dogs and rhesus monkeys with bile fistulae.
Tse FL; Dain JG; Kalafsky G
Biopharm Drug Dispos; 1995 Apr; 16(3):211-9. PubMed ID: 7787133
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic drug interaction between fexofenadine and fluvastatin mediated by organic anion-transporting polypeptides in rats.
Qiang F; Lee BJ; Lee W; Han HK
Eur J Pharm Sci; 2009 Jun; 37(3-4):413-7. PubMed ID: 19428223
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacokinetics of fluvastatin.
Scripture CD; Pieper JA
Clin Pharmacokinet; 2001; 40(4):263-81. PubMed ID: 11368292
[TBL] [Abstract][Full Text] [Related]
9. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.
Dahan A; Amidon GL
Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G371-7. PubMed ID: 19541926
[TBL] [Abstract][Full Text] [Related]
10. Regional intestinal permeability in rats of compounds with different physicochemical properties and transport mechanisms.
Fagerholm U; Lindahl A; Lennernäs H
J Pharm Pharmacol; 1997 Jul; 49(7):687-90. PubMed ID: 9255712
[TBL] [Abstract][Full Text] [Related]
11. Jejunal permeability and hepatic extraction of fluvastatin in humans.
Lindahl A; Sandström R; Ungell AL; Abrahamsson B; Knutson TW; Knutson L; Lennernäs H
Clin Pharmacol Ther; 1996 Nov; 60(5):493-503. PubMed ID: 8941022
[TBL] [Abstract][Full Text] [Related]
12. Steady-state pharmacokinetics of fluvastatin in healthy subjects following a new extended release fluvastatin tablet, Lescol XL.
Barilla D; Prasad P; Hubert M; Gumbhir-Shah K
Biopharm Drug Dispos; 2004 Mar; 25(2):51-9. PubMed ID: 14872552
[TBL] [Abstract][Full Text] [Related]
13. The difference in pharmacokinetics and pharmacodynamics between extended-release fluvastatin and immediate-release fluvastatin in healthy Chinese subjects.
Xu HR; Chen WL; Chu NN; Li XN; Zhu JR
J Biomed Biotechnol; 2012; 2012():386230. PubMed ID: 22811596
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers.
Tse FL; Jaffe JM; Troendle A
J Clin Pharmacol; 1992 Jul; 32(7):630-8. PubMed ID: 1640002
[TBL] [Abstract][Full Text] [Related]
15. Absorption and disposition of fluvastatin, an inhibitor of HMG-CoA reductase, in the rabbit.
Tse FL; Labbadia D
Biopharm Drug Dispos; 1992 May; 13(4):285-94. PubMed ID: 1600114
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of fluvastatin and specific drug interactions.
Smith HT; Jokubaitis LA; Troendle AJ; Hwang DS; Robinson WT
Am J Hypertens; 1993 Nov; 6(11 Pt 2):375S-382S. PubMed ID: 8297546
[TBL] [Abstract][Full Text] [Related]
17. Site-specific bidirectional efflux of 2,4-dinitrophenyl-S-glutathione, a substrate of multidrug resistance-associated proteins, in rat intestine and Caco-2 cells.
Yokooji T; Murakami T; Yumoto R; Nagai J; Takano M
J Pharm Pharmacol; 2007 Apr; 59(4):513-20. PubMed ID: 17430634
[TBL] [Abstract][Full Text] [Related]
18. Time-of-intake (morning versus evening) of extended-release fluvastatin in hyperlipemic patients is without influence on the pharmacodynamics (mevalonic acid excretion) and pharmacokinetics.
Fauler G; Abletshauser C; Erwa W; Löser R; Witschital K; März W
Int J Clin Pharmacol Ther; 2007 Jun; 45(6):328-34. PubMed ID: 17595890
[TBL] [Abstract][Full Text] [Related]
19. Safety, tolerability, and pharmacokinetics of an extended-release formulation of fluvastatin administered once daily to patients with primary hypercholesterolemia.
Sabia H; Prasad P; Smith HT; Stoltz RR; Rothenberg P
J Cardiovasc Pharmacol; 2001 May; 37(5):502-11. PubMed ID: 11336101
[TBL] [Abstract][Full Text] [Related]
20. Cellular uptake of fluvastatin, an inhibitor of HMG-CoA reductase, by rat cultured hepatocytes and human aortic endothelial cells.
Ohtawa M; Masuda N; Akasaka I; Nakashima A; Ochiai K; Moriyasu M
Br J Clin Pharmacol; 1999 Apr; 47(4):383-9. PubMed ID: 10233202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
